Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy
Sponsor: Incyte Corporation
This observational or N/A phase trial investigates MPN (Myeloproliferative Neoplasms) and is currently completed. Incyte Corporation leads this study, which shows 19 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2022 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
May 2021 — Jun 2022 [monthly]
Active Not Recruiting
▶ Show 14 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting
-
Dec 2019 — Jan 2021 [monthly]
Active Not Recruiting
-
May 2019 — Dec 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — May 2019 [monthly]
Recruiting
-
Aug 2018 — Mar 2019 [monthly]
Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
-
Oct 2017 — Feb 2018 [monthly]
Recruiting NA
-
Aug 2017 — Oct 2017 [monthly]
Recruiting NA
-
Jun 2017 — Aug 2017 [monthly]
Recruiting NA
-
Apr 2017 — Jun 2017 [monthly]
Recruiting NA
-
Feb 2017 — Apr 2017 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .